Tag

Vhb937

All articles tagged with #vhb937

biotech27 days ago

Novartis Halts ALS Drug After Phase 2 Failure, Deepening R&D Slump

Novartis has discontinued its amyotrophic lateral sclerosis (ALS) drug candidate VHB937 after a phase 2 trial failed to meet primary and secondary endpoints. The decision follows a series of recent clinical setbacks for the company, including failures in cardiovascular and muscle-wasting therapies, and prompts questions about its research strategy. While the ALS program is scrapped, development of the same drug for Alzheimer’s disease continues, as target validation remains stronger in that area. The company has also acquired a brain delivery platform from Sironax to bolster its neuroscience pipeline.

via Fierce Biotech|

#als #biotech #clinical-trials

pharma27 days ago

Novartis Halts ALS Drug VHB937 After Phase 2 Trial Misses All Endpoints

Novartis has discontinued development of VHB937, an experimental drug for amyotrophic lateral sclerosis (ALS), after its Phase 2 trial failed to meet primary and secondary endpoints. The trial, known as Astrals, involved 251 patients with early-stage ALS and compared the TREM2 stabilizer against a placebo. This setback extends a recent string of R&D failures for the Swiss pharmaceutical giant, including missed targets in cardiovascular and muscle-wasting disease trials. While the ALS program is scrapped, Novartis is continuing Phase 2 testing of the same compound for Alzheimer’s disease, where the target mechanism is considered more robust. The failure adds to a broader trend of unsuccessful clinical trials for TREM2-based therapies across the industry.

via Endpoints News|

#als #novartis #pharma